The estimated Net Worth of Paul B Manning is at least $12.6 million dollars as of 27 June 2024. Mr. Manning owns over 1,333,333 units of Verrica Pharmaceuticals Inc stock worth over $2,573,333 and over the last 9 years he sold VRCA stock worth over $9,999,998. In addition, he makes $0 as Chairman of the Board at Verrica Pharmaceuticals Inc.
Paul has made over 31 trades of the Verrica Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,333,333 units of VRCA stock worth $2,999,999 on 27 June 2024.
The largest trade he's ever made was buying 16,466,667 units of Verrica Pharmaceuticals Inc stock on 16 August 2023 worth over $14,820,000. On average, Paul trades about 592,587 units every 68 days since 2015. As of 27 June 2024 he still owns at least 1,333,333 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Mr. Manning stock trades at the bottom of the page.
Paul B. Manning is Chairman of the Board of the Company. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of various private companies. Within the past five years, Mr. Manning previously served on the Board of Directors of Dova Pharmaceuticals, Inc., Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our Board of Directors believes that Mr. Manning should serve as a director based upon his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.
Paul's mailing address filed with the SEC is Tech 4, 419, Davis Drive, Morrisville, Durham County, North Carolina, 27560, United States.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning et John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: